Viragen wieder ein Kauf
Seite 1 von 2 Neuester Beitrag: 25.07.03 14:36 | ||||
Eröffnet am: | 21.07.03 10:15 | von: Calibra21 | Anzahl Beiträge: | 27 |
Neuester Beitrag: | 25.07.03 14:36 | von: TB75F | Leser gesamt: | 4.979 |
Forum: | Hot-Stocks | Leser heute: | 4 | |
Bewertet mit: | ||||
Seite: < 1 | 2 > |
Der Abwärtstrendkanal ist voll intakt. Allerdings befindet sich der aktuelle Kurs
am Boden des Abwärtstrendkanals sodaß heute Kurse bis zu 22 Cents drin sind.
Das wären beim Aktuellen Kursniveau über 20 %. Bei der Nasdaqeröffnung wird erfahrungs
gemäß der Umsatz wieder anfangen zu steigen.
Den Zug nicht verpassen....
hier einige Anregungen, und wer nicht zuschlägt ist selbst schuld !
==================================================
die Ziele, die sich Viragen noch dieses Jahr gesetzt hat:
Autor: bladetrader 23.07.2003 - 12:57 Uhr
d.h. ist höchste zeit für news !!
=================================
2003 Goals - First Half Report
· Build Multiferon™ revenue
· Expand Multiferon™ indications and geographic approvals
· Enter into additional international supply and distribution agreements
· Report significant Avian Transgenics milestones
· Obtain debt financing by offering debentures convertible at a premium to market price
· Contain costs, cut cash burn rate, focus resources on priority programs
· Implement Director/Management stock-based compensation program
While it has been less than six months since setting these goals, I am pleased to report that tangible progress has been reported regarding all of these initiatives. We invite you to review these press announcements at www.Viragen.com. Our reported results demonstrate that our global Multiferon program is growing steadily and our R&D projects, including Avian Transgenic Technology and certain anti-cancer efforts, appear capable of fulfilling their promise. While our progress to date is encouraging, it is only the very beginning of our long-term strategy and vision. Over the next twelve months, we expect to continue to report important commercial and scientific milestones, which build upon all of the previously mentioned goals, as well as include the following:
Beitrag drucken · Antworten
e-mail von viragen ! !!
Autor: bladetrader 23.07.2003 - 09:24 Uhr
hier ist auch schon die antwort von viragen, "we're working on pos.comm...", was immer das auch beuten mag. / hoffen wir das Beste !
************************
Dear XXXXX,
Thnaks for your interest in Viragen, Inc.
Our Chairman, Carl Singer, issued a Midyear Report which can be reviewed at
http://www.viragen.com/pressreleases/2003/virpr06182003.htm
The report includes potential news topics for future release.
I wish I could be more revealing, but consistent with Federal securities
laws, Viragen cannot provide any investor with selective disclosure.
However, we are working on new communications which we hope will be
positively received.
We really appreciate your support. very best regards, Doug
Douglas W. Calder
Director of Communications
Viragen, Inc. (AMEX: "VRA")
http://www.viragen.com
(954) 233-8746
Beitrag drucken · Antworten
AW: diesen kurs will ich wieder sehen !!!!! USD 2,50 !!
Autor: bladetrader 22.07.2003 - 19:46 Uhr
Habe grad an Viragen eine e-mail geschickt. wollte wissen was da los ist, wann endlich news kommen.
halt euch auf den laufenden.
Beitrag drucken · Antworten
diesen kurs will ich wieder sehen !!!!! USD 2,50 !!
Autor: bladetrader 22.07.2003 - 19:28 Uhr
Beitrag drucken · Antworten
nach oben !!!
Autor: bladetrader 22.07.2003 - 19:27 Uhr
06.12.2000 19:03:00
Was kam zuerst, das Huhn oder das Ei? In der genetischen Forschung ist das Huhn ein relativer Spätzünder und hatte am heutigen Mittwoch sein Debut in Schottland.
Die Viragen Inc. und das britische Roslin Institut, das uns Dolly das Schaf brachte (das erste erfolgreich geklonte ausgewachsene Säugetier), präsentierten ein genetisch verändertes Huhn, das bei der Entwicklung von Medikamenten behilflich sein könnte.
Die Aktie von Viragen blieben unverändert bei $2.38. Der Handel der Aktie wurde am Dienstag ausgesetzt. Zudem gab man bekannt, dass die Investmentbank Ladenburg Thalmann $2.5 Millionen seiner Anteile zwischen dem 7. Dezember und 11.Januar erwerben möchte
Beitrag drucken · Antworten
AW: Es geht nach oben .. irgendwann
Autor: bladetrader 22.07.2003 - 12:38 Uhr
Hier ein Auszug aus der website.
'Viragen hat sich auf natürl. Interferon spezialisiert, markteintritte erfolgt und wird noch erfolgen'
*************************************
Multiferon is expected to offer a safe and effective first-line or second-line therapy for many viral and malignant indications including chronic hepatitis C and certain cancers.
Multiferon is approved in Sweden and Mexico for the second-line treatment of any and all diseases in which recombinant (synthetic) interferon therapy failed or the patient was unable to tolerate the regimen, probably due to the formation of neutralizing antibodies. Multiferon is also approved for sale in the following countries as a second-line therapy for the treatment of Hairy Cell Leukemia (HCL) and Chronic Myelogenous Leukemia (CML): Czech Republic, Egypt, Hong Kong, Indonesia, Myanmar, South Africa and Thailand. The expanded indications approved in Sweden and Mexico are expected in these countries shortly. Regulatory approval processes are also underway in a number of other South American, Middle East and Far East territories
Beitrag drucken · Antworten
AW: Es geht nach oben .. irgendwann
Autor: bladetrader 22.07.2003 - 10:31 Uhr
nein, nein, mach dir mal keine sorgen. der firma gehts blendend. sonst würden nicht so viele investoren geld reinpumpen. nur noch ein wenig geduld bis zu den news, und wir werden geil belohnt werden. der kurs hat riesen potential. viragen bewegt sich in einem millarden-markt !
Beitrag drucken · Antworten
Es geht nach oben .. irgendwann
Autor: wowka 22.07.2003 - 09:55 Uhr
Ich bin bei 0.32 eingestiegen,
habe bei 0.22 nachgekauft,
werde wohl bei 0.12 nochmal zukaufen,
um dann bei 0.02 alles für wohltätige Ziele zu spenden 8-(
Beitrag drucken · Antworten
AW: VIRAGEN !! Countdown läuft !! im AMEX gehts steil nach oben !!!
Autor: bladetrader 22.07.2003 - 09:25 Uhr
oh gott - oh gott !! mir wird jetzt langsam auch ganz schlecht.
wann brigen die endlich die news !! wird langsam höchste zeit !
möge gott uns beistehen !
Beitrag drucken · Antworten
AW: VIRAGEN !! Countdown läuft !! im AMEX gehts steil nach oben !!!
Autor: bladetrader 18.07.2003 - 15:52 Uhr
DAUMEN drücken ! Amex-Start !!!!!
Beitrag drucken · Antworten
AW: Und abwärts, und dann Sprung nach OBEN !!!!
Autor: bladetrader 18.07.2003 - 10:50 Uhr
Beitrag drucken · Antworten
AW: Und abwärts, und dann Sprung nach unten
Autor: bladetrader 18.07.2003 - 10:49 Uhr
hatte das in den letzten wochen so oft erlebt, daß ich aktien, von denen ich eigentlich überzeugt war, vorschnell vekauft habe, nur weil andere aktien auf einmal in den fokus geraten sind, um diese dann zu kaufen.
meist sind die aktien, die ich dann verkauft habe um bis zu 200% gestiegen.
hätte mich in den arsch treten können.
nochmal passiert mir das nicht. Bin zwar auch eher der Daytrader und Zocker aber diese Chance lass ich mir nicht entgehen.
Anti-cancer Activity
PLANTATION, FLORIDA – July 23rd, 2003 - Viragen, Inc. (AMEX: “VRA”) today commented on a Japanese interferon study from the July 17th online issue of Nature (http://www.nature.com). Viragen’s research and development team believes the study further confirms the potential of treating many forms of cancer with its natural human alpha interferon drug, Multiferon™.
The research article titled, “Integration of interferon-alpha/beta signaling to p53 responses in tumor suppression and antiviral defense”, reports that interferon activates the tumor-suppressor gene called p53. The researchers found that the joint activity of interferon and p53 induced programmed cell death (apoptosis) in cancerous cells and in antiviral immune responses. The p53 gene has been the subject of extensive worldwide research for several years and is regarded as a common denominator in human cancer. The authors concluded that their study suggested the possible usefulness of treating human cancers with interferon in combination with chemotherapeutic drugs that activate p53.
“These are exciting findings which could explain why we are achieving positive results in treating certain cancers with natural alpha interferon,” stated Professor William Stimson, Viragen’s Director of Research (Emeritus). “We have conducted several studies utilizing our leukocyte-derived interferon for the treatment of certain cancers, including malignant melanoma. Our results have been encouraging and suggest a strong trend toward increased overall survival along with natural interferon demonstrating an excellent safety and toxicity profile. This new Japanese study may well point to the reason for the potent anti-tumor activity of interferon and suggest new combined therapeutic regimens for treating many forms of malignant disease.”
Produced by human white blood cells, alpha interferon is a protein that occurs naturally in the body and helps improve the body’s natural defenses by preparing it to fight viruses and attack and slow the growth of tumors. Since the action of alpha interferon is directed at the cell itself, its anti-viral and anti-cancer functions are extremely broad-ranging, making it a potential therapy for a wide range of diseases.
Dr. Karen Jervis, Viragen’s Director of Technology and Projects Coordinator, discussed some of the advantages that might be offered by a natural human alpha interferon therapy. “The worldwide interferon market is dominated by recombinant (synthetic) interferons which are prescribed for a variety of viral and malignant diseases such as hepatitis C and cancer. Despite being the prevalent therapy, many patients do not benefit when treated with recombinant interferon. It is widely reported that a significant percentage of these patients form unfavorable immune responses that reduce the effectiveness of the therapy and/or may be unable to tolerate the adverse side effects often associated with treatment. This can lead to a lack of compliance and/or withdrawal from treatment and increased costs. It seems advantageous to offer these patients a natural alpha interferon as a ‘rescue therapy’ that closely mimics the human immune system’s natural defensive response while offering a more favorable side effect profile. Furthermore, natural alpha interferon offers multiple subtypes of interferon which may work together as a ‘cocktail-in-one’, while recombinant versions only exhibit a single subtype.” Viragen offers Multiferon™ at a cost which is competitive with recombinant interferon regimens.
Background:
The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond to standard therapy. In some instances, recombinant interferon is rejected by the patient's immune system, usually caused by the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side effects sometimes associated with recombinant therapy. High doses of recombinant interferon may cause serious, even life-threatening side effects.
Multiferon™ - The Natural Choice
Viragen has observed that in many cases, especially when higher dosages are required, its natural interferon appears to offer many advantages to therapy with recombinant interferons.
· Natural alpha interferon is very similar to interferon secreted by the human leukocytes during a normal virus infection, significantly lowering the risk of the drug being rejected.
· Natural alpha interferon contains the multiple subtype composition that is characteristic of interferon produced by the human body. It is believed that this results in a broader spectrum of specific anti-viral and immunoregulatory activity with the subtypes acting synergistically to give a wide-ranging response.
· Natural alpha interferon is significantly less immunogenic than recombinant interferon and does not cause the formation of neutralizing antibodies. It is far better tolerated by patients with fewer side effects and thus allows for higher doses to be administered to maximize the benefits of the therapy.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen’s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the biopharmaceutical industry.
--------------------------------------------------
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
VRA : VIRAGEN INC (AMEX) 2:43 AM ET
Last Trade 0.230 Open 0.200
Change +0.030
Previous Close 0.200
% Change +15.00%
Today's High 0.300
P/E -1.82
Today's Low 0.190
Market Cap 48.19 Mil
52 Wk High 0.670
52 Wk Low 0.050
Volume 50,015,400 Avg Daily Vol 9,570,000